C
Cyrano Therapeutics
Sensory Disorder | Loss of Taste & Smell | Smell and Taste Disorders
About Cyrano Therapeutics
Cyrano Therapeutics is a healthcare startup focused on developing innovative treatments for sensory disorders, specifically the loss of smell and taste. The company operates in the medical and pharmaceutical market, targeting individuals suffering from sensory impairments, which are often overlooked but have a profound impact on quality of life. Cyrano Therapeutics' core product is an intranasal spray aimed at treating and restoring smell and taste functions. This product addresses a significant unmet need, particularly among older adults, where the prevalence of sensory impairments increases with age. The business model revolves around the development, clinical testing, and eventual commercialization of this intranasal spray. Revenue is generated through product sales, partnerships with healthcare providers, and potential licensing agreements. Cyrano Therapeutics aims to improve the well-being and nutrition of its clients by restoring their sensory functions, thereby enhancing their overall quality of life.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2014
- Headquarters
- Delray Beach, United States
- Employees
- 7
- Open positions
- None listed
- Dealroom signal
- 46.4/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Tech for Medical Professionals, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2c
Latest news
Press, funding announcements and product moves mentioning Cyrano Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jan 2024 | $9M | $64M | Lumira Ventures · Remiges Ventures · Institute for Commercialization of Florida Technology | ↗ |
| LATE VCEquity / VC | Feb 2023 | $0 | — | Remiges Ventures | — |
Growth signals
Latest recorded traffic for Cyrano Therapeutics is 2.5K monthly website visits, up 197.6% over the last three months. Cyrano Therapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A4 investors entered at this stage
DNV capital
Lumira Ventures
Remiges Ventures
Institute for Commercialization of Florida Technology
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Cyrano Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Cyrano Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.